ICER releases draft evidence report on therapies for severe asthma

16 September 2021 - Public comment period now open until 14 October 2021; requests to make oral comment during public ...

Read more →

Branded price variation in the United States drug market, 2010 to 2019

13 September 2021 - Branded drug prices command considerable attention in the United States yet defining a drug’s price is not ...

Read more →

ICER publishes evidence report on treatments for myasthenia gravis

10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...

Read more →

Controversy over using quality adjusted life years in cost effectiveness analyses: a systematic literature review

8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value ...

Read more →

ICER to assess treatments for COVID-19

26 August 2021 - Report will be subject of Midwest CEPAC meeting in April 2022; Draft Scoping Document open to public ...

Read more →

ICER to assess novel agents to prevent chemotherapy-induced neutropenia

25 August 2021 - Report will be subject of CTAF meeting in April 2022; draft scoping document open to public comment ...

Read more →

ICER uses observational real world evidence to update 2018 assessment on therapies for hereditary angioedema, finds therapies far less cost effective than earlier estimates

24 August 2021 - Patients initiating therapy in real world dataset had less frequent baseline attack rates than rates from clinical ...

Read more →

ICER releases draft evidence report on mavacamten for hypertrophic cardiomyopathy

18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...

Read more →

ICER publishes final evidence report and policy recommendations on therapies for atopic dermatitis

17 August 2021 - Given uncertainty about safety data on oral JAK inhibitors for other indications, a narrow majority of the ...

Read more →

ICER publishes final evidence report and policy recommendations on aducanumab for Alzheimer’s disease

5 August 2021 - Independent appraisal committee unanimously determined the evidence is not adequate to demonstrate that aducanumab provides a net ...

Read more →

ICER releases draft evidence report on therapies for myasthenia gravis

22 July 2021 - Public comment period now open until 18 August 2021; requests to make oral comment during public meeting ...

Read more →

Aduhelm pros and cons debated at ICER meeting

16 July 2021 - Biogen officials defended the company's Alzheimer's drug and criticised ICER's cost effectiveness report today at a meeting ...

Read more →

ICER publishes evidence report on therapies for atopic dermatitis

9 July 2021 - Evidence demonstrates the JAK inhibitors abrocitinib and upadacitinib are effective treatments for atopic dermatitis, but safety concerns ...

Read more →

ICER to test principle of fair access to fairly priced pharmaceuticals

2 July 2021 - The controversial approval last month by the FDA of Aduhelm (aducanumab) for patients with early-stage Alzheimer’s disease ...

Read more →

ICER to assess treatment for type 2 diabetes

30 June 2021 - Report will be subject of New England CEPAC meeting in January 2022; draft scoping document open ...

Read more →